Video

Q&A With Anne Cross from Washington University School of Medicine: Additional Treatments Could Provide Benefit to Patients With Multiple Sclerosis

Author(s):

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

Anne H. Cross from the Washington University School of Medicine discussed this potential new treatment during the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis. Cross said that while these treatments have not been approved for patients with the relapsing form of the condition. She also added that if they are approved it will be important that only properly trained healthcare professionals provide them to patients.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.